Cannabis Linked to 2x Risk of Heart Disease Death, Scientists Discover
New research suggests that cannabis use is linked to twice the risk of death from cardiovascular disease, and is also associated with increased risk of other major adverse cardiovascular events (MACE).
Cannabis is being legalized in more and more places worldwide, increasing medicinal and recreational use – but it may warrant closer monitoring by health professionals. The researchers here, led by a team from the University of Toulouse in France, wanted to look more closely at potential health risks that had previously been flagged.
They looked at 24 previous studies published between 2016 and 2023, involving around 200 million people. Overall, the increased risk linked to cannabis use was 29 percent for acute coronary syndrome (reduced blood flow to the heart), 20 percent for strokes, and 100 percent for cardiovascular disease mortality.
"The findings reveal positive associations between cannabis use and MACE," write the researchers in their published paper. "These findings should encourage investigating cannabis use in all patients presenting with serious cardiovascular disorders."
There are some limitations worth bearing in mind here. The studies included in the research differed in terms of how they defined cannabis use, relied on self-reporting, and didn't measure use of the drug over time. That makes them less statistically robust.
The research also notes a high risk of bias in the majority of studies investigated, due to the way they were structured.
And it's important to say the research doesn't show direct cause and effect, only an association. It's possible that other factors not considered here are driving both cannabis use and heart health issues in certain groups of people.
Nevertheless, the large number of people surveyed on their real-world use of cannabis counts in the study's favor. It also has more recent data than many other studies, and we know that cannabis use and composition is changing over time.
That's enough to warrant deeper investigation into the possible health risks.
"Legalizing the drug and expanding its medical use worldwide have likely contributed to profound changes in the general perception of cannabis and to the overall rise in cannabis consumption," write the researchers.
"Consequently, users' profiles and consumption habits profoundly differ from those in the 2010s, especially as cannabis products show an increasing trend in potency, with rising concentrations of delta-9-tetrahydrocannabinol (THC)."
Further research is absolutely needed here, not least to determine whether the chemicals and compounds in cannabis – of which there are hundreds – could be leading to these health risks, and how taking cannabis in different forms, such as inhalables or edibles, might have an influence.
Previous studies have already shown how the drug can increase the risk of cancer, and significantly alter our DNA, for example. Cannabis could also trigger psychosis through the impact it has on the brain.
The new study is accompanied by an editorial written by epidemiologists Stanton Glanz and Lynn Silver, from the University of California San Francisco. In it, Glanz and Silver argue that as cannabis use rises, more should be done to educate people about the risks – as has been done with cigarettes.
"Specifically, cannabis should be treated like tobacco: not criminalized but discouraged, with protection of bystanders from secondhand exposure," they write.
The research has been published in the journal Heart.
5 Daily Habits Could Be Causing Your Liver Serious Harm
FDA-Approved Sleeping Pill Slows Alzheimer's Tangles in Pre-Clinical Trial
Risk of Sleep Breathing Disorder Set to Rise 45% by End of Century
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Medtronic (MDT) Appoints Dr. Joon Sup Lee to Board of Directors
Medtronic plc (NYSE:MDT) is one of the 11 best European stocks to invest in. On June 23, the company announced the appointment of Dr. Joon Sup Lee as an independent director to its Board of Directors. The appointment went into effect on June 18, 2025. A healthcare specialist in the laboratory testing an Oncology-related product. Dr. Lee's appointment was a result of Medtronic increasing the size of its Board. The new director will serve on the Board's Science and Technology Committee and the Compensation and Talent Committee. Dr. Lee is currently the CEO of Emory Healthcare, Inc., overseeing Georgia's most comprehensive academic health system. Before joining Emory Healthcare, Dr. Lee was the executive director of the University of Pittsburgh Medical Center's (UPMC) Heart and Vascular Institute from 2018 to 2020. He was also a professor of medicine at the University of Pittsburgh School of Medicine. He held various leadership roles at UPMC, including Director of Interventional Cardiology and Director of the Cardiac Catheterization Laboratory. Medtronic plc (NYSE:MDT) is an Irish-domiciled healthcare technology company. It develops and sells medical devices and therapies for chronic conditions across four main segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Its top products include heart devices, spinal implants, surgical tools, insulin pumps, and neuromodulation systems. Medtronic serves over 79 million patients annually in more than 150 countries. While we acknowledge the potential of MDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment
GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the treatment of active lupus nephritis (LN). The approval applies to children aged five years and above. A pharmacist looking at a prescription bottle of gastrointestinal drugs. Benlysta autoinjector is the first-of-its-kind treatment option for at-home administration. The drug is a B-lymphocyte stimulator (BLyS)-specific inhibiting monoclonal antibody. It works by binding to soluble BLyS, which inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. It does not bind B cells directly. The 200 mg/mL autoinjector was previously approved for pediatric patients with active systemic lupus erythematosus (SLE) in 2024. Benlysta was the first and only approved biologic for both SLE and lupus nephritis in over 50 years, including for the pediatric population. The autoinjector will be available for patients and their caregivers immediately. GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company. It researches, develops, and sells medicines and vaccines for infectious diseases, HIV, respiratory conditions, cancer, and immune-related disorders. Its key products include Shingrix (shingles vaccine), Nucala (asthma), and HIV treatments through its ViiV Healthcare joint venture. While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion
Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed the acquisition of Regulus Therapeutics. Following the acquisition, the shares of Regulus ceased trading on the NASDAQ exchange, and the company became a fully owned subsidiary of Novartis. lucarista/ The acquisition marks a crucial step in the company's effort to advance the clinical development of a potential first-in-class medicine for autosomal dominant polycystic kidney disease. Regulus Joins Novartis with Farabursen, an investigational next-generation oligonucleotide aiming to reduce the growth of cysts and kidney size. Novartis is a global healthcare company dedicated to discovering and developing innovative medicines that improve and extend people's lives. It also focuses on addressing significant medical challenges, including cancer and rare genetic disorders, by prioritizing research and development, as well as innovative access approaches. Novartis AG (NYSE:NVS) is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines to improve and extend people's lives. It also focuses on using science-based innovation to address significant healthcare challenges. Novartis operates in over 100 countries, with the US accounting for about one-third of its revenue. While we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data